

S/N 09/825,765

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Yumi Yokoyama et al.

Examiner: Unknown

Serial No.: 09/825,765

Group Art Unit: 1645

Filed: April 4, 2001

Docket: 600.491US2

Title: GENETIC MODIFICATION OF ENDOSTATIN

RECEIVED
MAR - 7 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for review in connection with the above-identified patent application. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants.

In accordance with 37 C.F.R. § 1.98(d), copies of the listed documents are not provided as these references were previously cited by or submitted to the U.S. Patent Office in connection with Applicants' prior U.S. application, Serial No. 09/825,129, filed on April 3, 2001, which is relied upon for an earlier filing date under 35 U.S.C. § 120.

Applicants respectfully request consideration of these references during prosecution of the above-identified matter. The Examiner is invited to contact the Applicants' Representatives at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

YUMI YOKOYAMA ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date February 15, 2002

By Janet E. Embretson
Janet E. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this 15 day of February, 2002.

Alisia G. Dunbar

Name

Signature

Alisia G. Dunbar